Dr. Andrew Snyder (Monash University) joins the show to discuss the current biotech landscape: rising M&A and IPO activity, ...

But what if one of them encounters significant competition soon? That's what some investors believe might happen, given ...

Significant news coverage and COVID-19 flashbacks have driven investors into biotech stocks over the past week.

An expert from Northway Biotech and Lithuania’s Minister of Economy and Innovation talk about how the country is poised to be ...

FDA drug approvals are reshaping biotech stocks—track key decisions, FDA leadership turmoil, and volatility. Click for a look ...

Krystal Biotech leverages its HSV-1 gene delivery platform, with VYJUVEK generating strong cash flow. Read why I rate KRYS ...

Biotech stocks are gaining momentum on M&A activity, cancer drug launches and upcoming autoimmune treatment data.

While some biotech investors are focused on the weight-loss market (and with good reason), breakthroughs are happening ...

Sara Ahmed ’26, a student in the MBA for Executives program, drew on her background in biotech to craft a speaker series ...

The broker has been looking over the biotech giant's guidance downgrade. The post 'Blood on the Street': What is Bell Potter ...

Chris Gibson built the pioneering AI biotech Recursion Pharmaceuticals on a foundation of bold promises. But after more than ...